Abstract Search

ea0029p1149 | Neuroendocrinology | ICEECE2012

An initial dose of 7.5 mg Tolvaptan is safe and effective in the treatment of hyponatremia caused by SIADH

Cuesta M. , Gomez-Hoyos E. , Montanez C. , Martin P. , Marcuello C. , de Miguel P. , Calle A. , Runkle I.

Tolvaptan (TV), an ADH V2-receptor blocker, is useful in treating SIADH-induced hyponatremia. Maximum aquaresis following 15 mg TV occurs on day 1, when excess body water is greatest. This can cause a sharp rise in natremia, and poses a risk of overcorrection. Our aim was to evaluate an initial dose of 7.5 mg.Methods: We studied 7 hospitalized patients with SIADH (4 females), median age 80 (5795), with nadir natremias (Nap) ranging from ...

0 shares

ea0026p597 | Clinical case reports | ECE2011

Use of our last pills of iopanoic acid in a 33-year-old patient in acute refractory pulmonary edema and thyroid storm: requiem for a useful therapeutic agent

Hoyos E Gomez , Novoa P de Miguel , Zorrilla C Montanez , de la Torre N Garcia , Freixes M Curras , Freire R Bover , Pascual A Calle , de la Vega I Runkle

Introduction: The contrast agents iopanoic acid and ipodate are potent inhibitors of thyroid function, reducing type I deodinase T3 generation, inhibiting thyroid liberation of T4 and T3, and T3 receptor binding, with off-label use in hyperthyroid emergencies. However, since the interruption of iopanoic acid production this year, neither agent is currently available in Spain.Case report: A 34-year-old male was ...

0 shares

Endocrine Abstracts

An initial dose of 7.5 mg Tolvaptan is safe and effective in the treatment of hyponatremia caused by SIADH

Use of our last pills of iopanoic acid in a 33-year-old patient in acute refractory pulmonary edema and thyroid storm: requiem for a useful therapeutic agent

BiosciAbstracts